Rocket Lab (NASDAQ: RKLB) shares have been under significant pressure recently, but analysts argue the selloff has created one of the more compelling setups in the new-space sector.
A 24/7 Wall St. price target of $120.99, against a current price of $61.96, implies roughly 95.3% upside over the next 12 months, supporting a buy rating with a 50% confidence level.
That moderate confidence reflects the binary nature of two major upcoming events: the first flight of the Neutron rocket and the pending Iridium acquisition, either of which could materially shift the stock’s trajectory.
RKLB shares are down 22.6% over the past month and 11.2% year to date, though they remain up 34.2% over the past year and a remarkable 231.5% over the past five years.
The stock sits well off its 52-week high of $151 but comfortably above its 52-week low of $37.57, leaving a wide range for directional movement in either direction.
Fundamentals have continued to firm despite the recent price weakness, with Q2 FY2026 revenue hitting a record $234 million, up 62% year over year, while backlog grew to $2.36 billion.
Non-GAAP gross margin expanded to 41.5% from 36.9%, and CEO Peter Beck described the launch environment as extreme, noting customers are locking in Neutron slots because “launch has never been so constrained.”
The bull thesis rests on compounding backlog growth and a string of major contract wins, including a $397 million Flatellite award, an $816 million Space Development Agency Tracking Layer contract, and a seat in the $17.9 billion Golden Dome program alongside Raytheon.
Neutron carries an average selling price of $50 million to $55 million per launch, and Beck has stated he has “zero issues in selling full price neutrons pre-test flights,” targeting Q4 2026 delivery to the pad.
The pending Iridium deal adds another layer of potential upside, bringing 2.5 million subscribers and $870 million in annual revenue into Rocket Lab’s business mix if completed on schedule.
Bears, however, point to stretched valuation metrics, with RKLB trading at a price-to-sales ratio of 52.4 while posting a Q2 GAAP net loss of $49.3 million and FY2025 free cash flow of negative $321.8 million.
Dilution has also been significant, with $1.08 billion raised through the ATM in Q2 alone, adding meaningful share count pressure for existing investors.
Neutron’s timeline has already slipped once following a Stage 1 tank test failure, and a further delay into 2027 combined with integration stumbles would point to a bear-case price near $94.84.
Compared to peers, Rocket Lab’s $2.36 billion backlog and diversified revenue profile put it in a materially stronger position than AST SpaceMobile (NASDAQ: ASTS), which carries $150 million to $200 million in 2026 revenue guidance and a $1.30 billion backlog.
Kratos Defense (NASDAQ: KTOS) has posted a negative 40.7% year-to-date return versus RKLB’s negative 18.5%, suggesting the market is already awarding Rocket Lab a meaningful scarcity premium in the defense-adjacent space sector.
The 24/7 Wall St. long-range price targets project RKLB reaching $197.33 in 2027, $265.97 in 2028, $338.75 in 2029, and $384.70 by 2030, assuming Neutron scales to full cadence and the Iridium deal closes on schedule.
Those projections also assume continued Space Force and SDA contract wins, with significant upside or downside possible depending on Neutron ASP expansion or delays to the Golden Dome buildout.
The buy case strengthens materially if Neutron reaches the pad in Q4 2026 and Q3 revenue lands within the guided range of $250 million to $265 million.
Investors should remain cautious, however, if Neutron slips past mid-2027 or if Iridium’s regulatory approval process encounters unexpected delays.
For now, RKLB’s combination of backlog quality, high-profile contract wins, and transformative catalysts gives the stock rare long-term visibility in a sector where execution risk remains elevated.
